Phathom Insider Sale Signals Shifting Confidence in Its Valuation
Phathom’s insider selling sparks debate: is the gastrointestinal drug pipeline over‑valued? Read the latest 4‑form analysis and market insight.
4 minutes to read
PHATHOM PHARMACEUTICALS INC
Phathom Insider Buys Back 28,000 Shares, Boosting Holdings Amid GI Therapy Outlook
Phathom insiders boost holdings amid a GI‑focused drug push, signaling confidence in a 2027 cash‑flow turnaround despite current negative earnings.
3 minutes to read
Phathom Shares Surge as Insider Buying Signals Confidence: What It Means for Investors
Insider buying by Phathom director Parikh Asit signals confidence amid the company’s 188% annual return and upcoming clinical milestones.
5 minutes to read
Phathom’s Board Buys RSUs, Signaling Confidence in GI Drug Pipeline
Phathom’s board buys RSUs, boosting confidence in its GI drug pipeline – see why insider buying signals growth prospects and how it may impact the stock.
3 minutes to read
Phathom Insider Move: Parikh Asit Shifts Shares to Trust—No Sell‑Off, Just Asset Re‑Allocation
Phathom insider transaction: Parikh Asit sells 40,000 shares but immediately places them in a spouse‑benefit trust, indicating a wealth‑management move that’s neutral for the stock while investors keep an eye on its oncology pipeline.
3 minutes to read
Phathom Insider Trades Show Confidence Amid Price Declines – Key Takeaways for Investors
Insightful look at Phathom Pharma’s insider trades: Breedlove’s 11% stake boost amid price swings, highlighting executive confidence and future upside potential.
3 minutes to read
Phathom Insider Buy Signals Value: 8,750 Shares at 34% Discount – What Investors Must Know
Phathom Pharmaceuticals insider buy: 8,750 shares at $10.30—below $15.14—signals long‑term confidence in GI therapeutics and a potential value play amid low P/E, regulatory hurdles.
4 minutes to read